Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fixed-dose vs Concentration-controlled MMF in Lupus Nephritis
NCT03920059Phase 4Terminated
- Sponsor
- Chulalongkorn University
- Start
- Aug 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of mycophenolate mofetil in lupus nephritis (LN) (2 arms), sponsored by Chulalongkorn University. Primary endpoint: Response rate at 48 week of therapy. Started Aug 2019; status: terminated.
02
Drugs
mycophenolate mofetil
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT03920059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03920059.